Triple Negative Breast Cancer News and Research

RSS

New DEAR1 gene predicts local recurrence in early-onset breast cancer

A newly discovered gene known as DEAR1 is mutated in breast cancer and is an independent predictor of local recurrence-free survival in early-onset breast cancer, a research team headed by scientists at The University of Texas M. D. Anderson Cancer Center reports in the journal PLoS Medicine.

5 May 2009

Possible new treatments options for triple-negative breast cancer

Brian Rowan, Ph.D., professor of Cancer Research for the Tulane Cancer Center, is studying treatment options for an aggressive type of breast cancer that is prevalent in New Orleans among African-American women - triple-negative breast cancer.

5 Apr 2009

EGFR inhibitors show promise for obesity

Once-promising drugs that were abandoned in the fight against breast cancer still could be effective in obese patients, new research suggests.

1 Dec 2008

Breastfeeding could reduce risk of aggressive form of breast cancer that disproportionately affects black, younger women

Breastfeeding for at least six months might lower the risk of developing so-called "triple negative" breast cancer, an aggressive form of the disease that is more common in black and younger women, according to a study published on Monday in the journal Cancer, the Seattle Post-Intelligencer reports (Paulson, Seattle Post-Intelligencer, 8/24).

26 Aug 2008

BiPar Sciences presents data for novel DNA repair inhibitor

BiPar Sciences, Inc. today announced the results of first-in-human clinical studies of its lead product, BSI-201, in patients with solid tumors.

2 Jun 2008

Triple-negative breast cancers doesn't always mean cancer spread

Triple-negative breast cancers are a heterogeneous group and may not always be associated with lymph node spread, a new study shows.

13 Apr 2008

Survival shortened when estrogen or progesterone receptor negative breast cancer spreads to the brain

Two studies from Mayo Clinic's site in Jacksonville, Fla., of women whose breast cancer spread to their brain, have found that women whose tumors do not have estrogen or progesterone receptors have the worst overall outcomes.

17 Dec 2007

Tumors less than 1 centimeter in size can be aggressive and may require maximum therapy

Breast tumors that are 1 centimeter in size or smaller - no more than 0.4 inch in length - can still be very aggressive and may require more intensive therapy than is routinely offered today, say researchers at Mayo Clinic in Jacksonville, Fla.

17 Dec 2007

Why cisplatin kills breast cancer cells when other drugs fail

The cancerous cells of some individuals with breast cancer lack expression of two cell surface proteins, the estrogen and progesterone receptors, and do not express increased amounts of HER2.

20 Apr 2007

New research may help identify patients most likely to benefit from cisplatin treatment

Researchers at the Massachusetts General Hospital (MGH) Cancer Center have identified a subgroup of hard-to-treat breast cancers that may be sensitive to the drug cisplatin, rarely used in the treatment of breast tumors.

20 Apr 2007